Michael J Hershman
Royal Liverpool University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael J Hershman.
Laboratory Investigation | 2006
Tim F Bullen; Sharon Forrest; Fiona Campbell; Andrew Dodson; Michael J Hershman; D. Mark Pritchard; Jerrold R. Turner; Marshall H. Montrose; Alastair J.M. Watson
Intestinal epithelial cells migrate from the base of the crypt to the villi where they are shed. However, little is known about the cell shedding process. We have studied the role of apoptosis and wound healing mechanisms in cell shedding from human small intestinal epithelium. A method preparing paraffin sections of human small intestine that preserves cell shedding was developed. A total of 14 417 villus sections were studied. The relationship of cell shedding to leukocytes (CD45), macrophages (CD68) and blood vessels (CD34) were studied by immunohistochemistry. Apoptotic cells were identified using the M30 antibody against cleaved cytokeratin 18 and an antibody against cleaved caspase-3. Potential wound healing mechanisms were studied using antibodies against Zona Occludens-1 (ZO-1) and phosphorylated myosin light chains (MLCs). We found that 5.3% of villus sections contained a shedding cell. An eosin-positive gap was often seen within the epithelial monolayer beneath shedding cells. Shedding was not associated with leukocytes, macrophages or blood vessels. Cells always underwent apoptosis during ejection from the monolayer. Apoptotic bodies were never seen in the monolayer but morphologically normal cells that were positive for M30 or cleaved caspase-3 were often seen. ZO-1 protein was usually (41/42) localized to the apical pole of cells neighboring a shedding event. Phosphorylated MLCs could be identified in 50% of shedding events. In conclusion, cell shedding is associated with apoptosis though it remains unclear whether apoptosis initiates shedding. It is also associated with phosphorylation of MLCs; a process associated previously with wound healing.
Colorectal Disease | 2003
Michael J Hershman; A. Sun Myint; C. Makin
Objective Despite recent advances, surgery remains the mainstay for the management of rectal carcinoma. The conventional surgical treatment for low rectal carcinoma is total mesorectal excision. This results in either abdomino‐perineal excision of the rectum (APER) with permanent colostomy or low anterior resection (LAR) usually with a covering stoma. Local resection is an alternative treatment option and this could be offered either using manual trans‐anal resection (TAR) or transanal endoscopic microsurgery (TEM) if the tumour is situated higher.
Cancer | 1995
Tim Helliwell; Andrew P. King; Michael Raraty; Conrad Wittram; Anthony I. Morris; Sun Myint; Michael J Hershman
Background. A 46‐year‐old man presented with recurrent anemia and polyarthralgia. Investigations revealed a mass in the ileal mesentery, which was resected. Results of routine histologic examination suggested a diagnosis of synovial sarcoma, a rare malignancy usually not reported at this site.
British Journal of Radiology | 2017
Arthur Sun Myint; Fraser McLean Smith; Simon Gollins; Helen Wong; Christopher Rao; Karen Whitmarsh; Raj Sripadam; Paul Rooney; Michael J Hershman; Zsolt Fekete; Kate Perkins; D. Mark Pritchard
OBJECTIVE A watch and wait policy for patients with a clinical complete response (cCR) after external beam chemoradiotherapy (EBCRT) for rectal cancer is an attractive option. However, approximately one-third of tumours will regrow, which requires surgical salvage for cure. We assessed whether contact X-ray brachytherapy (CXB) can improve organ preservation by avoiding surgery for local regrowth. METHODS From our institutional database, we identified 200 of 573 patients treated by CXB from 2003 to 2012. Median age was 74 years (range 32-94), and 134 (67%) patients were males. Histology was confirmed in all patients and was staged using CT scan, MRI or endorectal ultrasound. All patients received combined CXB and EBCRT, except 17 (8.5%) who had CXB alone. RESULTS Initial cCR was achieved in 144/200 (72%) patients. 38/56 (68%) patients who had residual tumour received immediate salvage surgery. 16/144 (11%) patients developed local relapse after cCR, and 124/144 (86%) maintained cCR. At median follow up of 2.7 years, 161 (80.5%) patients were free of cancer. The main late toxicity was bleeding (28%). Organ preservation was achieved in 124/200 (62%) patients. CONCLUSION Our data suggest that CXB can reduce local regrowth to 11% compared with around 30% after EBCRT alone. Organ preservation of 62% achieved was higher than reported in most published watch and wait studies. Advances in knowledge: CXB is a promising treatment option to avoid salvage surgery for local regrowth, which can improve the chance of organ preservation in patients who are not suitable for or refuse surgery.
Annals of The Royal College of Surgeons of England | 2002
James Francombe; Michael J Hershman
This study assesses the practicality, mortality and morbidity of the STAR procedure for debulking of large rectal tumours prior to transanal endoscopic microsurgery.
Diseases of The Colon & Rectum | 2008
Paul Antoine Lehur; Angelo Stuto; Michel Fantoli; Roberto D. Villani; Michel Queralto; Franck Lazorthes; Michael J Hershman; Alfonso Carriero; François Pigot; Guillaume Meurette; Prashanthi Narisetty; Richard Villet
Ejso | 2001
A Pirayesh; Y Chee; Tim Helliwell; Michael J Hershman; Sj Leinster; M.V. Fordham; G.J. Poston
Clinical Oncology | 2007
A. Sun Myint; Robert Grieve; A. McDonald; Edward Levine; S Ramani; Kate Perkins; Helen Wong; C. Makin; Michael J Hershman
Hospital Medicine | 2001
James Francombe; Paul S Carter; Michael J Hershman
Clinical Oncology | 2007
Michael J Hershman; A. Sun Myint